Clinical Trial Update: R-DA-EDOCH Versus R-CEOP90, With/Without Upfront Auto-HSCT in Young Patients With High-risk DLBCL [Phase 3]

View source ↗

Summary

Phase 3 trial comparing R-DA-EDOCH versus R-CEOP90 with/without upfront autologous HSCT in young high-risk diffuse large B-cell lymphoma patients; status not sp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• R-CEOP90
• R-DA-EDOCH

Snippet

Sponsor: Fujian Medical University | Conditions: Diffuse Large B-cell Lymphoma | Phase 3 | Status: UNKNOWN